U.S. Markets
Novo Nordisk (NOVOB DC) does not expect to see a biosimilar of semaglutide in China this year, it is protected until April 2027 in China
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
